Why Eli Lilly’s $1 Billion AI Bet Could Reshape Drug Discovery

By David Beren Updated Feb 17, 10:56AM EST · Published Feb 16, 2:00PM EST

Quick Read

Eli Lilly (LLY) reported Q4 EPS of $7.54 versus $6.67 expected. Eli Lilly projected 2026 revenue of $80-83B.
Eli Lilly’s Mounjaro revenue surged 110% to $7.4B in Q4. Zepbound revenue jumped 123% to $4.2B.
Eli Lilly achieved operating margins of 45.6% and net margins of 31.7%.

Follow 24/7 Wall St. on Google

This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.

Why Eli Lilly’s $1 Billion AI Bet Could Reshape Drug Discovery — © 24/7 Wall St.

Editor’s note: A prior version of this article stated Eli Lilly and Nvidia had funded a supercomputer, when the commitment was for the co-innovation lab. This article has been updated to reflect the change. If there are further requests please send to [email protected]

As of February 13, 2026, shares of Eli Lilly (NYSE:LLY | LLY Price Prediction) were trading at $1,040, just 5.8% below the stock’s all-time high. Retail sentiment has turned decisively bullish following the company’s Q4 2025 earnings beat, with Reddit’s sentiment score climbing from neutral (57.3) to bullish (65.7) over the past week. The catalyst? Eli Lilly overdelivered on Earnings Per Share relative to estimates and projected 2026 revenue of $80-83 billion.

An infographic titled 'Eli Lilly (LLY) Investment Snapshot' with a dark blue header. It is divided into three sections: 1. THE INVESTMENT: Eli Lilly (LLY) shows a pill bottle and a bar chart with an upward trend. Text indicates Eli Lilly is a 'Pharmaceutical Leader' focused on 'Diabetes & Obesity', with a price of '$1,081.07 (Feb 4, 2026)' and a '$1 Trillion Market Cap Milestone' trophy icon. 2. SOCIAL SENTIMENT SCORE displays a gauge with a needle pointing to the green 'BULLISH' section, showing a score of '65.7 BULLISH Weekly Score' improved from 57.3 (Neutral). 3. KEY SCORE DRIVERS (TODAY) lists three drivers: 'Strong Q4 2025 Earnings Beat' (with an upward trending bar chart icon) detailing EPS of $7.54 vs. $6.74 est. and Revenue of $19.29B vs. $18.14B est.; 'Robust 2026 Guidance' (with a calendar icon) showing a Profit Forecast of $33.50-$35; and 'High Weight-Loss Drug Demand' (with a weighing scale icon) driven by Mounjaro & Zepbound. The infographic uses blue, green, and white colors. — This infographic provides a snapshot of Eli Lilly’s (LLY) investment profile, highlighting its current bullish social sentiment score of 65.7, driven by a strong Q4 2025 earnings beat and robust 2026 guidance.

Eli Lilly +7% premarket after $7.54 EPS vs $6.67 and forecasting 2026 profit $33.50‑$35 on strong weight‑loss drug demand
by Reddit user in wallstreetbets

Why Investors Are Turning Bullish on Eli Lilly

The company’s GLP-1 franchise is delivering staggering results. Mounjaro revenue surged 110% to $7.4 billion, while Zepbound jumped 123% to $4.2 billion in Q4 alone. As one r/wallstreetbets user noted: “Eli Lilly +7% premarket after announcing earnings per share and forecasting 2026 profit on strong weight-loss drug demand.” This isn’t just about current sales. Eli Lilly built a $1.5 billion stockpile of orforglipron, its oral GLP-1 candidate, ahead of an anticipated April 2026 FDA decision. That’s aggressive positioning for rapid market capture.

But the real differentiator is AI. In October 2025, Lilly committed $1 billion to build a co-innovation lab with Nvidia (NASDAQ:NVDA) designed to interrogate biology at scale. By January 2026, the companies had established a co-innovation lab that links clinical data with Nvidia’s computational capabilities in real time. Chief Scientific Officer Daniel Skovronsky noted the company “achieved positive outcomes for nearly all R&D key events in 2025, a rare set of results in this industry.”

Three factors support continued momentum:

Eli Lilly became the first healthcare company to reach a $1 trillion market capitalization
Operating margins hit 45.6% with net margins of 31.7%, exceptional for pharma
The company’s AI platform gives it a competitive edge in drug discovery speed and cost efficiency

The Path to $1,350

Analysts maintain a consensus target of $1,201, with 18 analysts rating it Strong Buy and zero Sell ratings. But some see higher potential with a $1,350 price target, which reflects confidence that Eli Lilly’s combination of GLP-1 dominance, AI-accelerated pipeline, and manufacturing scale will drive sustained outperformance. With quarterly revenue growth of 42.6% and a pipeline delivering results at rates that exceed industry norms, the company has momentum to break through resistance. Novo Nordisk (NYSE:NVO) faces its own challenges, projecting -5% to -13% sales growth in 2026 amid pricing pressures, creating an opportunity for Lilly to capture additional market share.

About the Author David Beren →

David Beren has been a Flywheel Publishing contributor since 2022. Writing for 24/7 Wall St. since 2023, David loves to write about topics of all shapes and sizes. As a technology expert, David focuses heavily on consumer electronics brands, automobiles, and general technology. He has previously written for LifeWire, formerly About.com. As a part-time freelance writer, David’s “day job” has been working on and leading social media for multiple Fortune 100 brands. David loves the flexibility of this field and its ability to reach customers exactly where they like to spend their time. Additionally, David previously published his own blog, TmoNews.com, which reached 3 million readers in its first year. In addition to freelance and social media work, David loves to spend time with his family and children and relive the glory days of video game consoles by playing any retro game console he can get his hands on.